– WSJ
Eli Lilly Says Results From Phase 3 Trial Of Donanemab Presented At Alzheimer’s Association Conference; Study Showed Donanemab Significantly Slowed Cognitive And Functional Decline In People With Early Symptomatic Alzheimer’s Disease
Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year
